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ABSTRACT  
Background: A significant number of neonates with congenital heart disease present with a life-
threatening illness in the neonatal period where survival depends on timely diagnosis, 
management and referral.  
Objectives: To determine the incidence and prognosis of critical congenital heart disease in 
neonates admitted to Charlotte Maxeke Johannesburg Academic Hospital, and to compare it 
with international data.  
Method: This was a retrospective, descriptive study of neonates with critical and non-critical 
congenital heart disease admitted to Charlotte Maxeke Johannesburg Academic Hospital 
between 01 January 2006 and 31 December 2014. 
Results: There were 284 neonates diagnosed with congenital heart disease during the study 
period - 133 with critical congenital heart disease (8.2 per 1000 neonatal admissions) and 151 
with non-critical congenital heart disease (9.3 per 1000 neonatal admissions). The mortality 
rate for neonates with critical congenital heart disease was 61/133 (45.9%). 
Conclusion: Critical congenital heart disease is not commonly diagnosed in neonates, however 
the mortality rate is high. Increased awareness and screening programs may improve early 
diagnosis and allow timeous intervention.    
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BACKGROUND  
Congenital heart disease (CHD) is one of the most common congenital anomalies [1]. The 
prevalence of CHD varies across populations and also over time [2]. These variations are in part 
due to the quality of data captured, such as completeness of diagnosis (prenatal and postnatal), 
and registration of cases, amongst other issues. Europe has a common database for CHD, 
comprised of population-based surveys that form part of the European Surveillance of 
Congenital Anomalies (EUROCAT) [2]. Data on CHD in low to middle income countries (LMICS), 
especially Africa is scarce, and studies often do not include indigenous inhabitants. The 
estimated global prevalence of CHD is 8 per 1000 live births [1]. Africa has the lowest reported 
birth prevalence of CHD (1.9 per 1000 live births) with the prevalence in South Africa estimated 
to be 0.6-0.8 per 1000 live births [1] [3]. This estimate may be due to under reporting, as many 
patients with CHD in Africa are missed [4].  
Critical congenital disease (CCHD) comprises cyanotic CHD and left-sided obstructive lesions 
which may present with or without cyanosis [5] (See Table 1). Survival of neonates with CCHD 
depends on timely diagnosis, management and referral [3]. These cardiac lesions require 
surgery or catheterization in the neonatal period to avoid death or severe morbidity [6]. The 
global incidence of CCHD is reported to be 2 – 3 per 1000 live births [4]. The incidence of CCHD 
is constant worldwide, but is thought to be underestimated in countries where prenatal 
ultrasound screening is not uniformly practiced [4]. Early diagnosis of CCHD relies on antenatal 
fetal anomaly screening and neonatal examination. In South Africa, most of the CCHD are not 
diagnosed before birth owing to limited antenatal screening for CCHD [4].   
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Normal neonatal examination does not exclude serious or life threatening cardiovascular 
malformations. About one third of babies with signs and symptoms of CHD are only diagnosed 
by 6 weeks of age and 57% by 3 months [7]. If every baby with signs and symptoms of CHD had 
an echocardiogram, half of them could have been diagnosed by 6 weeks and 76% by 3 months 
[7]. Routine neonatal echocardiography is, however, not feasible in South Africa due to 
resource constraints [8].  
Many neonates with CCHD are not diagnosed at birth, and late diagnosis of CCHD is associated 
with increased hospitalization and costs [9]. Late detection of CCHD is defined as diagnosis after 
the birth hospital discharge and approximately 23% of infants with CCHD are diagnosed late [9]. 
Late detection of CCHD is significantly associated with more hospital admissions (52%), longer 
duration of hospitalization (18%), and higher inpatient costs during infancy (35%) [9]. Improved 
screening for CCHD might help save cost in inpatient care during infancy. Early detection of 
CCHD is however not associated with a lower mortality for patients with significant CHD [9].  
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Table 1. Critical cyanotic heart lesions and left-sided obstructive lesions  
             
List of Critical cyanotic congenital heart lesions 
             
Tetralogy of Fallot 
Transposition of great arteries 
Hypoplastic right heart  
Tricuspid atresia 
Truncus arteriosus 
Double outlet right ventricle 
Single ventricle 
Total anomalous pulmonary venous return   
             
List of left-sided obstructive lesions  
             
Hypoplastic left heart 
Aortic stenosis 
Coarctation of aorta  
Interrupted aortic arch 
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The one year survival for infants with CCHD has been improving over time, yet the mortality 
remains high. One year survival for infants with CCHDs improved from 67.4% (1979-1993) to 
82.5% (1994-2005) [10]. Late diagnosis (diagnosis after birth hospital discharge) was also 
associated with improved one year survival [9]. One year survival was 71.7% for neonates with 
CCHD diagnosed within the first day of life, and was 82.5% for neonates with CCHD diagnosed 
after the first day of life (p < .001) [10]. This difference in mortality is likely due to more severe 
conditions being present among infants with CCHD that is detected early in the neonatal period 
[10]. Some infants with CCHD may not require corrective surgery in early infancy based on the 
severity of their cardiac lesions [5]. 
This study aims to describe the incidence and outcome of neonates presenting with CCHD at 
CMJAH over a 9 year period. 
 
METHODS 
This was a retrospective, descriptive study of all neonates with CCHD who were admitted to 
CMJAH between 01 January 2006 and 31 December 2014. CMJAH is a tertiary hospital with a 
cardiology and cardiac surgery service. There is a cluster of regional hospitals and midwife 
clinics which refer neonates to CMJAH for tertiary services.  
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Participants  
Inclusion criteria: 
All neonates (<28 days of life) who were admitted to CMJAH (neonatal and general paediatric 
wards) with a critical congenital cardiac defect were eligible for inclusion in the study. Critical 
congenital heart disease was defined as a group of heart defects that cause serious, life-
threatening symptoms and requires intervention within the early neonatal period or first year 
of life [4]. Neonates diagnosed with a CHD that was non-critical (non-CCHD) were also included 
in the study, but analyzed separately. Neonates with dysrhythmias (notably congenital heart 
block) were also included in the non-critical CHD group.  
Exclusion criteria: 
Neonates diagnosed with patent ductus arteriosus (PDA) only were excluded from the study, as 
the presence of a PDA varies with gestational age and can depend on changing physiology (such 
as fluid overload and sepsis). Neonates assessed by a paediatric cardiologist, but without a 
confirmed cardiac diagnosis were excluded. Neonates referred directly to the cardiothoracic 
unit from other hospitals were also excluded.   
For the purpose of the study, chromosomal abnormalities were defined as confirmed trisomy 
13, trisomy 18 and trisomy 21. Neonates who were dysmorphic but did not have a 
chromosomal diagnosis were analyzed with the group as having no chromosomal abnormality. 
Chromosomal analysis was not done routinely but requested at the discretion of the attending 
physician, based on clinical assessment.  There was no record of clinically dysmorphic babies 
who did not have a chromosome analysis done.   
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Database   
Data from the study was retrieved from the CMJAH neonatal database, as well as from the 
paediatric cardiology database. The REDcap neonatal database is used for the purpose of 
clinical audit [11]. Information is collected for each patient on discharge from the neonatal unit 
at CMJAH. Data is managed using REDcap (Research Electronic Data Capture), hosted by the 
University of the Witwatersrand [11]. Patient records from the paediatric cardiology 
department are also stored on an electronic database. Accuracy of data captured on the 
databases is checked at several stages of the data collection process. Data collected from the 
databases included: age at presentation, gestational age, birth weight, ethnicity, cardiac 
diagnosis (obtained by echocardiography or cardiac catheterization), surgical treatment, and 
survival to hospital discharge.   
Statistical analysis  
Data collected was entered into a Microsoft Excel spreadsheet (Microsoft, USA), and imported 
into a statistical software package SPPS version 23 (IBM, USA). Categorical variables were 
described using frequencies and percentages. Continuous variables had a normal distribution, 
so were described using mean and standard deviation. Neonates with CCHD were compared 
with those with non-critical CHD, with regard to characteristics and survival to hospital 
discharge. Patients who were discharged home and those who were transferred out of hospital 
were grouped together as survivors for the purpose of analysis. Categorical variables were 
compared using Chi Square analysis and continuous variables using unpaired tests. A p value of 
0.05 was considered to be statistically significant.  
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Ethics  
Ethics approval for the study was obtained from the Human Research Ethics Committee of the 
University of Witwatersrand: clearance certificate number M151001. 
 
RESULTS 
   Figure 1. Total number of neonates at each stage of the study 
 
 
 
A total of 1001/16 200 (6.2%) neonates admitted at CMJAH were referred for cardiac 
assessment. There were 133 neonates with CCHD (46.8%) (8.2/1000 neonatal admissions) and 
151 with non CCHD (53.2%) (9.3/1000 neonatal admissions).  Characteristics of neonates with 
CCHD and non CCHD are shown in Table 2-3.  
 
 16 200 neonatal 
admissions 
Cardiac 
assessment 1001 
CHD  
284 
CCHD  
133 
non-CCHD 
151 
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Gestational age, birth weight, and outcome were only available in 19 patients. There was no 
significant difference in birth weight between survivors and non-survivors (( 2.4kg (SD 0.7) vs 
2.7 kg (SD 0.8) p=0.3). Similarly there was no difference in gestational age between survivors 
and non-survivors (35.5 weeks (SD 2.6) vs 37 weeks (SD 3.2) p=0.3).     
 
Table 2. Characteristics of neonates with CCHD at CMJAH  
              
Cardiac diagnosis                      No of patients                    Surgical management                       Died                                 Chromosomal abnormalities 
CCHD                                               (n=133), n (%)           (n=44), n (%)                     (n=61), n (%)                       (n=4)       
              
Coarc     18 (13.5)                                     11 (61)      5/18 (28)               0 
HLH     15 (11.3)                                     0  (0)                    15/15 (100)          0 
TOF     19 (14.3)                                     5  (26)                        4/19 (21)                            2 
PA     22 (16.5)                                     6 (27)                                     10/22 (45)                            0 
TAPVD     2 (1.5)                   0  (0)                                     0/2 (0)           0 
DORV      9 (6.8)                      0  (0)                        2/9 (22)                                                1 
Truncus     1 (0.8)                   0  (0)                        0/1 (0)           0 
TGA     8 (6.0)                   5  (63)                  4/8 (50)                             0 
TA                       17 (12.8)                                     7 (41)                         9/17 (53)                                               0  
EA                       2 (1.5)                  2  (100)                         2/2 (100)                            0 
SV                       5 (3.7)                  1 (20)      2/5 (40)                             0 
IAA                       9 (6.8)                  5 (56)      6/9 (67)                             1 
Complex cyanotic CHD   6 (4.5)                                  2 (33)                   2/6 (33)            0 
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Table 3. Characteristics of neonates with non CCHD at CMJAH  
              
Cardiac diagnosis                         No of patients                      Surgical management                    Died                                 Chromosomal abnormalities 
Non-CCHD                                        (n=151), n (%)               (n=8), n (%)                         (n=11), n (%)                         (n=42)  
              
VSD         75 (49.7)                                      4  (5.3)                          3/75 (4)           13 
ECD     35 (23.2)                                      4  (11.4)                          6/35 (17.1)                            22 
ASD      34 (22.5)                                      0 (0)        2/34 (5.9)                            7 
CHB     7 (4.6)                   0 (0)        0/7 (0)           0 
 
 
Table 4. Characteristics of neonates with CCHD compared with neonates with non-CCHD with 
respect to cardiac surgery and survival to hospital discharge at CMJAH  
              
CCHD (n=133), n (%)     non-CCHD (n=151), n (%)  P value 
              
Surgical intervention           44 (33)                 8 (5.3)   < 0.05 
Survival to hospital discharge          72 (54)                 140 (92.7)  < 0.05 
 
Neonates with CCHD 
A significant number of neonates admitted at CMJAH with a CHD had CCHD 133/284 (46.9%). 
They were predominantly male (61%). The majority was diagnosed in the early neonatal period 
(within the first 7 days of life) 83/133 (62%). A significant number of neonates with CCHD died 
during the study period 61/133 (45.8%, p <0.05), as compared with neonates with non-CCHD. 
Only 44/133 (33%) neonates had surgery for their cardiac defects. In those children with CCHD, 
surgery was significantly associated with survival – 30/41 (73.1%) of those who had surgery 
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survived compared to 16/68 (23.9%) of those who did not have surgery (p<0.001). Outcome 
was unknown in 24 cases. There were 4/133 (3%) neonates diagnosed with a chromosomal 
abnormality. All of the neonates with CCHD diagnosed with a chromosomal disorder had either 
trisomy 13 or 18 respectively.    
Neonates with non-CCHD 
There were 151/284 (53.2%) neonates diagnosed with CHD that was non-critical. The majority 
was male (56%). Most were diagnosed in the late neonatal period (after the first 7 days of life, 
but before the first 28 days of life) 86/151 (57%). A total of 11/151 (7.3%) died during the study 
period. There were 8 neonates with non-CCHD (5.3%) who had surgery for their cardiac defect 
(VSD 4, ECD 4). A significant number of neonates with non-CCHD were diagnosed with a 
chromosomal disorder 42/151 (27.8%, p <0.05), as compared with neonates CCHD. The 
majority had trisomy 21  21/42 (50%).   
 
DISCUSSION 
Early diagnosis of CCHD relies on antenatal fetal anomaly screening and clinical examination. In 
South Africa, most CCHD are not diagnosed before birth, owing to the limited antenatal 
screening for CCHD [4]. The majority of newborns, mainly at midwife birth units and peripheral 
hospitals, do not get to be examined by members of paediatric staff. Thus neonates with CHD, 
especially CCHD at peripheral health centers are often missed.  
Examination of all newborn babies by a trained member of paediatric staff can help identify 
neonates with congenital disease [12]. The incidence of CHD is higher when all neonates are 
carefully examined by full-time members of paediatric staff, who actively looked for evidence of 
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CHD. The incidence of CHD at a tertiary paediatric hospital in South Africa was reported to be 
8.6 per 1000 live births, when all neonates were examined by a full time member of paediatric 
staff (compared with 5.3 per 1000 live births when only some neonates were examined) [12]. A 
significant number of the neonates with CHD (30%) were discovered after neonatal discharge 
[12]. Thus it is highly recommended that all newborn infants be routinely examined by trained 
member of paediatric staff, not only soon after delivery, but also at the time of postnatal check 
of the mother. Pulse oximetry can also be used to screen for CCHD, on all newborns prior to 
neonatal discharge. Pulse oximetry screening is an effective, noninvasive, and inexpensive tool 
allowing for early diagnosis of CCHD [4]. 
 
The use of pulse oximetry to screen for neonates with CCHD can help identify patients that 
require cardiac surgery early, and thus reduce the morbidity and mortality from CCHD [13]. In 
the absence of early detection, patients with CCHD are at risk for serious complications or 
death within the first days, or weeks of life [13]. The mortality rate was high amongst neonates 
with CCHD (46%), compared with approximately 25% reported in international literature [10]. 
Only 33% of neonates with CCHD had surgery for their cardiac defect. With appropriate care, 
the prognosis for patients with CCHD is excellent, with at least 85% expected to survive to 
adulthood [3].  
Neonates diagnosed with coarctation of the aorta, had the most number of cardiac surgeries 
11/18 (61%). The mortality rate for these patients was low 5/18 (28%), compared with 
neonates with other types CCHD in the present study. The mortality rate of neonates who 
undergo coarctation repair is very low, but the mortality of neonates with a birth weight of less 
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than 2.5kg is 24%, which is similar to the mortality rate in the current study [14]. In the local 
context, neonates with coarctaion of the aorta would therefore be preferred surgical 
candidates over neonates with more complex cardiac abnormalities. Pulmonary atresia was the 
most commonly diagnosed CCHD (16.5%), and the mortality rate for pulmonary atresia was 
high (43%). Hypoplastic left heart syndrome contributed significantly to the high mortality for 
neonates with CCHD 15/61 (25%). Patients with hypoplastic heart disease have a poor 
prognosis in the local context where neonatal cardiac surgery and heart transplantation is not 
feasible. Neonates with hypoplastic left heart in the current study all died, however, surgery is 
not offered to neonates with this condition in the study setting, as outcomes are poor with or 
without surgery.  
 
Advances made in the developed world in diagnostic options, as well as surgical and 
interventional management of CCHD have not been replicated in Africa. Every year 3000 
children die or remain disabled from their congenital heart conditions in South Africa, as 
paediatric cardiac services are unable to meet the high patient demand [3]. There is a shortage 
of paediatric cardiologists in South Africa, with only 24 practising in the country in 2008. This is 
far less than the international recommendation, that South Africa should have at least 88 
paediatric cardiologists. Paediatric cardiothoracic surgeons are also scarce, with only 12 
practicing in the country in 2008, and patient load of approximately 4500 children with CHD 
who required surgical intervention [3]. Another bottleneck that contributes to the high 
morbidity and mortality in patients with CCHD is the lack of theatre availability and 
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postoperative intensive care, which requires highly specialized medical and nursing 
management [3].     
A significant number of neonates with non-CCHD had a chromosomal disorder (28%), compared 
to those with CCHD (3%). It is not known how many non-dysmorphic neonates with a CHD had 
a chromosomal abnormality in the study setting. Chromosomal analysis was not routinely done 
on patients diagnosed with CHD. Only some of the neonates with a CHD had chromosomal 
analysis done based on the clinicians clinical assessment. It is therefore possible that in the 
absence of comprehensive genetic testing, genetic abnormalities were under reported in the 
current study.  Approximately 12% of infants with CHD have a chromosomal abnormality, 
Hartman et al [15]. CHD most likely to be associated with a chromosomal abnormality were 
interrupted aortic arch, atrioventricular septal defect, and double outlet right ventricle. The 
most common chromosomal abnormalities observed in international literature were trisomy 21 
(52.8%), trisomy 18 (12.8%), and 22q11.2 deletion 12.2%) [15]. For neonates with CCHD who 
had chromosomal analysis done in the study setting, trisomy 13 and 18 were the only 
chromosomal abnormalities detected in this subset of patients. For neonates with non-CCHD 50 
percent had trisomy 21 and the remaining 50 percent had either trisomy 13 or 18 respectively. 
Antenatal screening for congenital anomalies should be encouraged, as termination of 
pregnancy could be offered where anomalies associated with a high mortality are detected [5]. 
Clinicians should have a low threshold to test for chromosomal abnormalities in infants with 
CHD, especially those with certain types of CHDs [15].    
It is possible that prematurity could account for the high mortality rate in neonates with CCHD. 
Unfortunately birth weight and gestational age were unavailable in the majority of patients. 
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However, in those for whom this information was present, there was no difference in 
gestational age or birth weight between survivors and non-survivors.    
 
CONCLUSION 
Relatively few neonates were diagnosed with CCHD at CMJAH, compared with that reported in 
international literature, which reflects under diagnosis of neonates with congenital heart 
disease. This may be improved with a low cost intervention such as the use of neonatal pulse 
oximetry which is effective to screen for CCHD [4]. South Africa is a resource limited country 
with a shortage of medical staff and equipment. There is a shortage of nursing staff that would 
be relied upon for routine pulse oximetry screening for CCHD [4]. There is also a limited supply 
of pulse oximetry machines to screen for all neonates. In addition, the majority of neonates are 
discharged early (within 6 hours of birth) from health centers. Antenatal ultrasonography can 
also be used as an alternative screening tool for CCHD [4]. However only a few people are 
skilled to be able to detect significant congenital heart disease using antenatal ultrasonography 
in South Africa, and in other low income countries. Visible cyanosis on first examination of the 
newborn by medical staff can help identify patients with critical congenital heart disease. Most 
of the newborns are first examined by nursing staff trained in the care of the newborn to 
identify clinical signs, including cyanosis, that require further medical care. Neonates with 
clinical features suggestive of congenital heart disease can be referred for an echocardiogram.        
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LIMITATIONS  
This was a retrospective descriptive study of an existing database for neonates with CHD. The 
study relied on accuracy and completeness of data capture. Some of the information captured 
on the database was incomplete. Many of the neonates were referred in from outlying 
hospitals and did not have information on birth weight and gestational age. A significant 
number neonates were lost to follow up, thus their outcome could not be accurately 
determined. Also other confounding factors, such as the presence of comorbidity, could have 
contributed to the high mortality amongst neonates with CCHD.  Accurate figures for live births 
and neonatal admissions were not available, so an accurate incidence could not be established. 
A prospective national database for CHD with accurate birth records is required to determine 
the actual incidence of CHD.  
 
FUNDING 
The researcher incurred all the expenses of the research project. The cost of the research 
project was negligible. 
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Background: 
Congenital heart disease (CHD) is one of the most common congenital anomalies. Advances in 
paediatric care have resulted in an increased detection of patients born with CHD. With the 
improvement in medical knowledge and technology, many more babies are surviving, 
contributing to an increased prevalence of CHD. The introduction of echocardiography into 
clinical practice in the 1970’s has also greatly contributed to an increase in the CHD birth 
prevalence. The estimated global prevalence of CHD is 8 per 1,000 live births (1). The 
prevalence of CHD varies across populations and also over time. These variations are in part 
due to data completeness and capture, such as completeness of the diagnosis (prenatal and 
postnatal) and registration of cases, amongst other issues. Europe has a common database for 
CHD, comprised of population-based surveys that form part of the European Surveillance of 
Congenital Anomalies (EUROCAT) (2). Whereas data about CHD in Africa and developing 
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countries is scarce, and studies often do not include the indigenous inhabitants (1). Africa has 
the lowest reported birth prevalence of CHD (1.9 per 1,000 live births) with the prevalence in 
South Africa estimated to be 0.6-0.8 per 1,000 live births (3). This estimate might be under 
reporting the true prevalence in Africa as many patients with CHD are missed.  
Untreated CHD has considerable consequences and costs. Africa has lagged behind 
international acceptable standards in the management of CHD as many of these children go 
untreated. Every year in South Africa over 3000 children die or remain disabled from their 
congenital heart condition due to resource constraints. Survivors of CHD without surgical 
intervention require repeated hospital admissions and frequent follow-up visits (3). This places 
a significant financial and emotional burden on already impoverished caregivers and families. 
With the advancement of paediatric care, many more children are surviving to reach adulthood. 
The prevalence of CHD in the adult population is estimated to be 4 per 1,000 adults. As the 
survival rate of patients with CHD is expected to rise, producing large numbers of adults with 
congenital heart disease, more resources would be required to manage these patients. Adults 
with CHD require long term medical care, with its associated high costs (1). This poses medical, 
social, and economic challenges. Thus more adult cardiologists may need to be trained to deal 
with an increasing population of adults with CHD. Another important consideration is that for 
patients with CHD that require surgical repair, outcomes at older ages are often less favourable 
than at younger ages. Thus a high early detection rate, and surgical repair of patients with CHD, 
will result in better outcome (4). The birth prevalence of CHD differs between the different 
geographical areas. Worldwide ventricular septal defect (VSD) is the most commonly reported 
CHD subtype (5). In Africa the second most commonly reported CHD subtype is transposition of 
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the great arteries followed by atrial septal defect (ASD) (6). Whereas ASD is the second most 
common CHD in Europe, America and Asia, followed by patent ductus arteriosus. However a 
significant difference in the birth prevalence of the subtypes of CHD was noted between Asia, 
and Europe and America. There is a higher birth prevalence of pulmonary outflow tract 
obstruction defects in Asia (pulmonary stenosis and tetralogy of Fallot), and a lower birth 
prevalence of left ventricular outflow tract obstruction (coarctation of the aorta and aortic 
stenosis). Whereas Europe and North America reported a higher birth prevalence of left 
ventricular obstructive defects, and a lower birth prevalence of right ventricular out-flow tract 
lesions. No scientific explanation could be found to account for this difference in the birth 
prevalence of CHD subtypes in Asia, and North America and Europe. However genetics could 
account for the difference in the birth prevalence of CHD subtypes in the different continents 
(1) 
Normal neonatal examination does not exclude serious or life threatening cardiovascular 
malformations. About half of the babies noted to have a murmur in the early neonatal period 
have a structural heart disease. Wren et al found that about one third of the babies with signs 
and symptoms of CHD were only diagnosed by 6 weeks of age and 57% by 3 months. However 
if every baby with signs and symptoms of CHD had an echocardiogram, half of them could have 
been diagnosed by 6 weeks and 76% by three months. Thus early referral of babies with signs 
and symptoms of CHD for cardiology assessment and echocardiography is encouraged (7). 
However this is not feasible in our setting in South Africa, due to resource constraints. There is 
a shortage of paediatric cardiologists in South Africa. Only 24 paediatric cardiologists were 
practicing in South Africa in 2008, half of them in the private sector. This is far less than the 
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international recommendation, that South Africa should have at least 88 paediatric 
cardiologists. Paediatric cardiothoracic surgeons are also scarce, with only 12 practicing in the 
country. This is insufficient to successfully manage the high patient load, as every year in South 
Africa approximately 4500 children with CHD require surgical intervention. Another major 
deterrent to adequate care is the lack of theatre availability and postoperative intensive care, 
which requires highly specialized medical and nursing management (3)      
More recently, use of pulse oximetry is more practical and feasible in screening for critical 
congenital heart disease (CCHD). These are CHD requiring surgery or catheterization before 1 
year. Low oxygen saturation indicates hypoxemia, an early clinical sign of CCHD. Additional 
testing, repeat pulse oximetry and echocardiogram, is needed following an abnormal pulse 
oximetry screen to determine whether CCHD are present. However pulse oximetry screening 
for CCHD is not routinely done in South Africa. This is important as approximately 20% of CHD 
present with life-threatening illness in the neonatal period where survival depends on timely 
diagnosis, management and referral (8). There is a lack of information on babies presenting 
with a life threatening (critical) CHD in the neonatal period in South Africa.  
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Aim  
The study aims to determine the incidence and prognosis of neonates presenting with critical 
congenital heart disease (CCHD) at Charlotte Maxeke Johannesburg Academic Hospital (CMJAH) 
from 2006 to 2014. 
 
Objectives   
 To determine the incidence of critical congenital heart disease (CCHD) in neonates 
admitted during the first 28 days of life to CMJAH between 01 January 2006 to 31 
December 2014. 
 To compare the incidence of CCHD at CMJAH to the rest of Africa and the world. 
 To describe the different cardiac anomalies in patients with CCHD at CMJAH. 
 To establish how many infants with CCHD have chromosomal disorders. 
 To determine the survival to discharge of neonates with CCHD at CMJAH.  
 
Method 
This was a retrospective study describing newborn infants with CCHD at CMJAH. Patient 
information will be obtained from the CMJAH neonatal database, ward admissions registers 
and Paediatric Cardiology unit consult register. Cardiac anomalies (diagnosis) will be obtained 
from the Paediatric Cardiology unit register.  
Inclusion criteria: 
All neonates (<28 days of life) who were admitted to CMJAH (neonatal and general paediatric 
wards) between 01/01/2006 and 31/12/2014 with the diagnosis of CCHD will be eligible for 
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inclusion in the study. Patients with dysrhythmias (notably congenital heart block) will be 
included in the study.  
Exclusion criteria: 
Patients with the diagnosis of persistent pulmonary hypertension of the newborn (PPHN), 
patent ductus arteriosus (PDA) and myocarditis will be excluded from the study. This is because 
PPHN is not primarily a cardiac defect, whereas the presence of PDA varies with gestational age 
and can depend on changing physiology, such as fluid overload and sepsis.  
 
Data collection 
Demographic and clinical characteristics and survival to hospital discharge will be obtained for 
each patient. The data collection sheet is included in Appendix A. Records will be identified and 
allocated a data number. The key to patient identification and data numbers will be kept 
separately by the primary investigator.  
 
  
35 
 
Statistical analysis   
Data will be described using standard statistical methods. Categorical variables will be reported 
using frequencies and percentages. The distribution of continuous variables will be examined 
and either mean and standard deviation or the median and interquartile range will be used to 
describe these variables as appropriate. If there are sufficient numbers in each diagnostic 
category, the outcome to hospital discharge will be compared between the categories. The 
annual incidence will be compared between different years. Chi square analysis will be used for 
both these comparisons.    
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Timing 
 
 Apr May Jun Jul Aug Sep Oct Nov Dec Jan Feb Mar Apr May 
Literature 
review and 
preparation 
of the 
protocol 
              
Protocol 
assessment 
              
Ethics 
application 
              
Collection 
of data 
              
Data 
analysis 
              
Writing up 
thesis 
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Funding 
The researcher will incur the expenses of the research project. A personal computer will be 
utilized for data analysis. It is anticipated that the cost of the research project will be 
negligible. 
 
Ethics    
 
The research proposal will be submitted to the ethics committee of the University of 
Witwatersrand, for approval, prior to commencement of the study. Data used in the study will 
treated with confidentiality. The identifying markers of the patient obtained from the database, 
used for analysis, will be omitted. Identifying markers will be delinked using codes. Accessibility 
to the CMJAH database is restricted. Data retrieved from the database will be captured onto a 
personal computer of the primary investigator, which requires a code for access. As this is a 
retrospective record review study, informed consent from the patient is not required. 
Furthermore there will be no direct interaction with the patients, whose data will be analysed 
in the study. However consent will be obtained from the chief Executive Officer of CMJAH, for 
the proposed study.  
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Appendix A 
 
Study number:    
Demographics  Place of birth   
Age at presentation  CMJAH (20)  
0-7 days (1)  Other hospitals (21)   
8-20 days (2)  Clinic (22)  
Ethnicity   BBA (23)  
White (3)  Mechanical 
ventilation  
 
Coloured (4)  Yes (24)  
Indian (5)  No (25)  
Black (6)  Echocardiographic 
findings  
 
Gestational age   VSD (26)  
< 28 weeks (7)  ASD (27)  
28-30 weeks (8)  PDA (28)  
31-34 weeks (9)  PS (29)  
35-37 weeks (10)  TOF (30)  
> 37 weeks (11)  Coarc (31)  
Birth weight (12)  TGA (32)  
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800-999 (13)  Aos (33)  
1000-1499 (14)  Other (34)  
1500-1999 (15)  Investigations and 
treatment  
 
2000-3999 (16)  Cardiac 
catheterization (35)  
 
>4000 (17)  Operation (36)  
Chromosomal 
disorder 
 Medical management 
(37)  
 
Yes (18)  Outcome   
No (19)  Survival to hospital 
discharge (38) 
 
  Died  (39)  
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